biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > Sometimes it's just timing:

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon May 05, 2023 3:09pm

250 Views

Post# 35433634

RE:Sometimes it's just timing:

BTI's Dr. Jeffrey Cummings is quoted in this article today:

Another New Alzheimer's Drug: What Promising Trial Results Mean for Treatment - Scientific American

prophetoffactz wrote: $78.087.92 | 11.29%

New 52-week high for Prothena and closing in on its all-time high. Big boost in the neuroscience space, neurodegeneration, amyloid-beta, and Alzheimer's with recent trial results in the sector. Rathjen tweeted about BTI's amyloid-beta opportunity in the past given Biogen's advancement. Dr. Jeffrey Cumming is on BTI's Scientific Advisory Board and is a leading scientist in Alzheimer's. He's worked with Biogen. Previously he said success with Biogen's amyloid-beta drug could open the flood gates in the field to an investment boom. More than one beta-amyloid trial has helped boost confidence recently. Are the flood gates opening now? BTI has long had Alzheimer's on its website as an opportunity. Is now the time? Is the new confidence in the field boosting confidence in Prothena's interest in its licensing deal? Mark Day once press released:

"Several significant breakthroughs were made in the last year. The most exciting for me was with Alzheimer's disease. Biogen demonstrated their aducanumab could slow the progression of Alzheimer's disease in mild-to-moderate patients. This truly was a first and shows that when you prioritize science, you can yield truly astounding results." news release

Has beta-amyloid now been sorted out with clinical trial evidence unleashing an investment boom? BTI also has the acquired Alzheimer's program. RNAi has also been proven in neuroscience recently as never before boosting confidence. Is investment in the brain about to go crazy?

Mark Day:

"And now, as CEO of biOasis, I find myself right in the middle of this new era in neuroscience with what I have previously called, "one of the most unique and promising blood-brain barrier technologies of our time." Despite all the advances in neuroscience, the ability to transport drugs across the blood-brain barrier has remained elusive, something I believe biOasis and our Transcend Platform can address." News release

Chiesi is also about to become a strategic player in Lysosomal Storage as the brain becomes a key investment area given Denali's human trial results, and with gene therapy.

Is now the time for BTI?